Randomised clinical trial: the DPP-4 inhibitor, vildagliptin, inhibits gastric accommodation and increases glucagon-like peptide-1 plasma levels in healthy volunteers

Effect of acute peppermint oil administration on gastric sensorimotor function and nutrient tolerance in health

(2013) A. Papathanasopoulos et al.   NEUROGASTROENTEROLOGY AND MOTILITY

Review article: a comparison of glucagon-like peptides 1 and 2

(2012) P. Janssen et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Clinical Pharmacokinetics and Pharmacodynamics of Vildagliptin

(2012) Yan-Ling He   CLINICAL PHARMACOKINETICS

Effect of the GLP-1 analog liraglutide on satiation and gastric sensorimotor function during nutrient-drink ingestion

(2012) A Rotondo et al.   INTERNATIONAL JOURNAL OF OBESITY

Intragastric pressure during food intake: a physiological and minimally invasive method to assess gastric accommodation

(2011) P. Janssen et al.   NEUROGASTROENTEROLOGY AND MOTILITY

Glucagon-like peptide-1 relaxes gastric antrum through nitric oxide in mice

(2010) Alessandra Rotondo et al.   PEPTIDES

GLP-1 regulates gastroduodenal motility involving cholinergic pathways

(2009) j. schirra et al.   NEUROGASTROENTEROLOGY AND MOTILITY

DPP4 Inhibitors: a new approach in diabetes treatment

(2008) John Doupis et al.   ADVANCES IN THERAPY

The effect of dipeptidyl peptidase-4 inhibition on gastric volume, satiation and enteroendocrine secretion in type 2 diabetes: a double-blind, placebo-controlled crossover study

(2008) Adrian Vella et al.   CLINICAL ENDOCRINOLOGY

Evidence that vildagliptin attenuates deterioration of glycaemic control during 2-year treatment of patients with type 2 diabetes and mild hyperglycaemia*

(2008) W. A. Scherbaum et al.   DIABETES OBESITY & METABOLISM